Louis Garguilo on Muck Rack

Louis Garguilo

Verified
New York, Slingerlands
As seen in: Outsourced Pharma, LinkedIn, Life Science Leader, Pharmaceutical Online, Bioprocess Online, Cell & Gene, Drug Discovery Online, Advancing RNA
Covers:  Currently cover drug development and manufacturing outsourcing, and biotechs/pharma working with contract development and manufacturing organizations (CDMO). Also industry-related trends and topics
Doesn't Cover: drug discovery ; clinical trials management (although I do cover clinical trial material - supply chain) ; commercial drug sales
Chief Editor, Outsourced Pharma www.OutsourcedPharma.com. Tweets/retweets/comments my own.

Get in touch with Louis

Contact Louis, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Louis Garguilo’s Biography

Read Full Bio →

Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuanc…

Louis Garguilo’s Journalist Portfolio

Which States Are Best To Locate Your Biotech?

Which States Are Best To Locate Your Biotech?

How would you go about looking for a modest-sized facility in the U.S. to establish your own development and …

View article →
Bristol Myers Squibb Buys Mirati: Signal Or Symptom?

Bristol Myers Squibb Buys Mirati: Signal Or Symptom?

This discussion goes well beyond the recent Bristol Myers Squibb deal for Mirati Therapeutics, to thoughts on…

View article →
Oh, Oligonucleotides! Everybody Wants In

Oh, Oligonucleotides! Everybody Wants In

"We’re working on oligonucleotides,” says the bubbling biotech. “We can do oligos!” cries the eager CDMO. So …

View article →
AI Beats Back Bad Batches

AI Beats Back Bad Batches

"I look from a supply-chain perspective,” says AI / supply-chain expert Tingling Dai, “discovery, development…

View article →
Ex-Pfizer Pro Tired Of The Word "Strategic"

Ex-Pfizer Pro Tired Of The Word "Strategic"

A few months past the culmination of a 31-year career at Pfizer, Francis Dumont has this seminal thought on d…

View article →

Articles

Accelerate Your Next In Vivo CAR-T Program

|
By Louis Garguilo Verified
| Outsourced Pharma
Balancing in vivo potency and safety Achieve targeted, durable CAR expression while limiting off-target toxicity and immune reactions Complex formulation and conjugation Combine genetic payloads with delivery systems deliver precise control Expanded analytical requirements Advanced bioanalytical methods are used to characterize both vector and formulation attributes Cross-modality GMP scale-up End-to-end solutions manage viral vector or RNA-LNP production, formulation, and fill/finish New...
Open in Who Shared Issue with article?

Bridging Innovation & Clinical Reality In ADC And AOC Development

|
By Louis Garguilo Verified
| Outsourced Pharma
If you're developing an antibody-drug conjugate (ADC) or antibody-oligonucleotide conjugate (AOC), the science may be the easiest part. The harder work is building a development program that actually holds up under clinical and regulatory scrutiny. Regulatory and bioconjugation specialists Jeffrey Mocny and Nicolas Camper lay out where programs most often run into trouble, and it's almost always earlier than developers expect.
Open in Who Shared Issue with article?

Top 5 Challenges In Antibody-Oligonucleotide Manufacturing

|
By Ian Glassford, Louis Garguilo Verified
| Outsourced Pharma
Guest Column | July 10, 2026 By Ian Glassford, VP of Bioconjugation Development & Technical Excellence Antibody-oligonucleotide conjugates (AOCs) combine the targeting precision of antibodies with the gene-modulating power of oligonucleotides, short nucleic acids that can silence, splice, or redirect gene expression.
Open in Who Shared Issue with article?
See all 10,740 licensed articles (10,746 Total)

Interview

See all →

What was your first job as a journalist?

I consider my first job was as a paperboy, delivering a local daily on foot. Next was as a beat reporter for credits in journalism school.

Have you ever used a typewriter?

Oh, yes. Walked into my first journalism class at Syracuse University and there was a shiny typewriter on every desk.

What does it mean to be a journalist?

I believe to a certain level, all journalism has to be what we used to call "investigative." You have to dig deep to be helpful to readers.
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified